切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2011, Vol. 05 ›› Issue (06) : 465 -470. doi: 10.3877/cma.j.issn.1674-0793.2011.06.003

所属专题: 文献

论著

miR-338-3p在肝癌组织中的表达及意义
黄晓卉1, 陈连周1, 苏乔1, 姚亚楠2, 张珑涓1, 李雯1, 毕熲1, 曾文涛1, 汪谦3,()   
  1. 1. 510080 广州,中山大学附属第一医院外科实验室
    2. 510080 广州,中山大学附属第一医院外科实验室(《中华普通外科学文献(电子版)》杂志编辑部)
    3. 510080 广州,中山大学附属第一医院肝胆外科
  • 收稿日期:2011-07-07 出版日期:2011-12-01
  • 通信作者: 汪谦
  • 基金资助:
    国家自然科学基金资助项目(81071871,30672053); 广东省科技计划(2009B030801014); 广东省自然科学基金博士启动(10451008901006014, 9451008901002106)

Expression and significance of miR-338 in hepatocellular carcinoma tissue samples

Xiao-hui HUANG1, Lian-zhou CHEN1, Qiao SU1, Ya-nan YAO2, Long-juan ZHAN1, Wen LI1, Jiong BI1, Wen-tao ZENG1, Qian WANG3,()   

  1. 1. Laboratory of surgery, The first Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
  • Received:2011-07-07 Published:2011-12-01
  • Corresponding author: Qian WANG
  • About author:
    Corresponding author:WANG Qian, Email:
引用本文:

黄晓卉, 陈连周, 苏乔, 姚亚楠, 张珑涓, 李雯, 毕熲, 曾文涛, 汪谦. miR-338-3p在肝癌组织中的表达及意义[J/OL]. 中华普通外科学文献(电子版), 2011, 05(06): 465-470.

Xiao-hui HUANG, Lian-zhou CHEN, Qiao SU, Ya-nan YAO, Long-juan ZHAN, Wen LI, Jiong BI, Wen-tao ZENG, Qian WANG. Expression and significance of miR-338 in hepatocellular carcinoma tissue samples[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(06): 465-470.

目的

检测miRNA在肝癌中的表达谱,探讨miR-338-3p在肝癌组织中的表达及与肝癌临床病理参数的关系和意义。

方法

采用液相芯片技术分析20对肝癌组织与其癌旁组织中114种miRNA表达谱的差异。Real-time RT-PCR验证另36对肝癌组织中miR-338-3p下调表达及其与肝癌临床参数的相关性。

结果

31种miRNA在肝癌组织与非肝癌组织间呈现差异表达,其中12种miRNA在癌组织的表达较癌旁组织上调,19种miRNA在癌组织中表达下调。miR-338-3p下调表达程度与肝癌恶性程度、肿瘤分化程度、肝内和肝外转移及门静脉癌栓有关,与患者性别、AFP、HBsAg、是否合并肝硬变等不相关(P < 0.01)。miR-338-3p的表达量肝癌组织低于非肿瘤组织,转移性肝癌低于非转移性癌组织,miR-338-3p的表达量随着肿瘤级别的增加而逐近降低(P < 0.01)。

结论

肝癌组织与癌旁组织之间存在miRNA差异表达,其中miR-338-3p下调表达程度与肝恶性行为相关。

Objective

To detect the profile of 114 microRNA (miRNA) expression in hepatocellular carcinoma and investigate the relationship of miR-338 expression with clinicopathological parameters.

Methods

A bead-based miRNA expression profiling method was performed on 20 pairs of surgically removed HCC and adjacent non-tumorous tissue (NT). Special miR-338 downregulations and miR-338 associated with clinical characteristics was validated in an extended samples set of 36 paired HCC and adjacent non-tumorous liver tissues by real-time reverse transcription polymerase chain reaction (RT-PCR) analysis.

Results

Among these 114 miRNA, 31 miRNA were differentially expressed between HCC and non-cancerous liver tissues with 12 miRNA upregulated and 19 miRNA downregulated in HCC. The downexpression levels of miR-338 cases were found to be significantly associated with vascular invasion, intrahepatic metastasis, tumor size and tumor grade. However, there was no significant difference between miR-338 expression and other clinicopathological parameters in HCC. miR-338 was chosen for expression analysis by real-time RT-PCR analysis in an additional independent set of 36 pairs of HCC and NT. The results showed that the mRNA expression level of miR-338 in HCC was lower than in NT (P < 0.01), the mRNA expression level of miR-338 in M was lower than in NM (P < 0.01) and decreased miR-338 expression was correlated with increasing stage of HCC (P < 0.01).

Conclusion

Our study suggests that miR-338 expression could have relevance to the clinical behavior of HCC.

表1 miRNA在肝癌与癌旁组织中的表达差异
miRNA名称 定位 P 肝癌组织中的表达强度 肝癌癌旁组织中的表达强度 在肝癌组织中表达上调/下调
let-7a 11q24.1 < 0.001 0.838 ± 0.154 1.510 ± 0.394 下调
miR-122a 18q21.31 < 0.00l 0.781 ± 0.116 1.507 ± 0.491 下调
miR-124a 8q12.3 < 0.001 0.984 ± 0.322 1.612 ± 0.261 下调
miR-125a 19q13.33 < 0.001 0.895 ± 0.295 1.544 ± 0.178 下调
miR-125b 21q21.1 < 0.001 0.718 ± 0.228 1.498 ± 0.488 下调
miR-126 9q34.3 < 0.001 0.741 ± 0.174 1.436 ± 0.244 下调
miR-126* 9q34.3 < 0.001 0.729 ± 0.233 1.159 ± 0.365 下调
miR-129 7q32.1 < 0.001 0.864 ± 0.489 1.534 ± 0.367 下调
miR-143 5q32 < 0.001 0.769 ± 0.249 1.481 ± 0.439 下调
miR-145 5q32 < 0.001 0.630 ± 0.211 1.491 ± 0.278 下调
miR-152 17p13.1 < 0.001 0.713 ± 0.258 1.493 ± 0.300 下调
miR-15a 13q14.2 < 0.001 0.904 ± 0.328 1.595 ± 0.317 下调
miR-185 22q11.21 < 0.001 0.810 ± 0.320 1.234 ± 0.627 下调
miR-194 1q41 < 0.00l 0.604 ± 0.346 1.463 ± 0.426 下调
miR-195 19p13.12 < 0.001 0.910 ± 0.215 1.557 ± 0.458 下调
miR-199a 19p.32.2 < 0.001 0.869 ± 0.302 1.289 ± 0.478 下调
miR-200a p36.33 < 0.001 0.919 ± 0.289 1.345 ± 0.339 下调
miR-27a 19p.32.2 < 0.001 0.769 ± 0.195 1.163 ± 0.248 下调
miR-338 17q25.3 < 0.001 0.743 ± 0.149 1.401 ± 0.273 下调
miR-107 10q23.31 < 0.001 1.633 ± 0.283 1.017 ± 0.257 上调
miR-128b P22.3 < 0.001 1.629 ± 0.361 1.014 ± 0.248 上调
miR-130a 11q12.1 < 0.001 1.789 ± 0.348 0.649 ± 0.187 上调
miR-16 13q14.2 < 0.001 1.326 ± 0.239 1.020 ± 0.202 上调
miR-17-5p 13q31.3 < 0.001 1.514 ± 0.372 1.022 ± 0.184 上调
miR-205 1q32.2 < 0.001 1.511 ± 0.213 1.008 ± 0.182 上调
miR-207 9p21.1 < 0.001 1.444 ± 0.262 1.016 ± 0.231 上调
miR-221 Xp11.3 < 0.001 1.681 ± 0.358 1.001 ± 0.245 上调
miR-222 Xp11.3 < 0.001 1.513 ± 0.312 0.949 ± 0.199 上调
miR-224 Xq28 < 0.001 1,756 ± 0.396 0.969 ± 0,228 上调
miR-24 19p13.1 < 0.001 1.458 ± 0.211 1.001 ± 0.214 上调
miR-25 7q22.1 < 0.001 1.614 ± 0.212 0.955 ± 0.158 上调
表2 miRNA-338与肝癌临床病理的相关性
图1 定量RT-PCR检测miR-338 mRNA表达
1
Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res, 2006,66(15):7390-7394.
2
Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA, 2004,101(32):11755-11760.
3
Peck D, Crawford ED, Ross KN, et al. A method for high-throughput gene expression signature analysis. Genome Biol, 2006,7(7):R61.
4
Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 2006,25(17):2537-2545.
5
Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res, 2007,67(13):6092-6099.
6
Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem, 2006,99(3):671-678.
7
Michael MZ, O’Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res, 2003,1(12):882-891.
8
Cimmino A, Calin GA, Fabbri M, et al. CM. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA, 2005,102 (39):13944-13949.
9
Cummins JM, He Y, Leary RJ, et al. The colorectal micro RNAome. Proc Natl Acad Sci USA, 2006,103(10):3687-3692.
10
Gaur A, Jewell DA, Liang Y, et al. Characterization of micro RNA expression levels and their biological correlates in human cancer cell lines. Cancer Res, 2007,67(6):2456-2468.
11
Wong TS, Liu XB, Wong BY, et al. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res, 2008,14(9):2588-2592.
12
Ma L, Teruya-Feldsteinet J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 2007,449(7163):682-688.
13
Tavazoie SF, Alarcónet C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 2008,451(7175):147-152.
[1] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[2] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[5] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6] 韩婧, 郝少龙, 康骅. 北京市单中心甲状腺癌患者临床特征的回顾分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 490-493.
[7] 黄一博, 李至彦, 林晨, 陶亮, 王萌, 管文贤. 胃癌根治术中淋巴结示踪剂的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 586-588.
[8] 胡宁宁, 赵延荣, 王栋, 王胜亮, 郭源. FMNL3与肝细胞癌肝移植受者预后的相关性研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 283-288.
[9] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[10] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[11] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[12] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[13] 郭诗翔, 谭明达, 王槐志. 胰头癌淋巴结清扫再思考[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 625-628.
[14] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[15] 王曦娅, 尹弘青, 丁伟, 徐滨, 于海源, 马东升, 邵军. 桥本背景下甲状腺乳头状癌多参数分析预测大容量淋巴结转移[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 548-554.
阅读次数
全文


摘要